Autophagy, a major lysosomal degradative pathway for organelles and long-lived or damaged proteins, Is essential for neuronal survival. We showed that neuronal autophagy is markedly defective in Alzheimer's disease (AD) and have implicated failure of lysosomal proteolysis as the key mechanism. Underscoring the pathogenic significance of autophagic-lysosomal dysregulation, we discovered that presenilin 1 (PSI) is essential for lysosomal acidification and that PS1 mutations causing AD disrupt this function. Moreover, partially restoring deficient lysosomal proteolytic function in a mouse model of amyloidosis substantially ameliorates AD-related pathology and memory deficits. Based on new evidence that APP mutations also impair autophagy, we propose In Aim 1 to define the underlying mechanism and whether or not autophagy alterations are common to APP mutations found in familial AD and App triplication in Down syndrome, and to other AD factors, e.g., cholesterol (Project 1) and cystatin C (Project 3). Contributions of upstream endocytic pathway disruption by these factors will also be explored with Projects 1, 3 and 4.
In Aim 2, consequences of impaired lysosomal proteolysis on development of AD-related neuropathology and memory defects will be investigated in mouse models and dynamically in. primary neurons using video-imaging. We found that inhibiting lysosomal proteolysis induces selective retrograde transport deficits and AD-like neuritic dystrophy. The molecular basis for these effects will be defined and evidence will be sought for a similar mechanism operating in mice expressing mutant PSI or App genes.
Aim 3 focuses on therapeutic interventions to prevent or reverse pathology and memory deficits In AD mouse models by enhancing lysosomal proteolytic efficiency. We identified a specific pharmacological class of agents able to modulate lysosomal pH Independently of vATPase, which will be defined in terms of mechanism and therapeutic efficacy in AD mouse models In comparison to new modulators of autophagy Induction. Our studies, the first to investigate autophagy systematically in AD, will firmly establish the pathogenic significance of autophagy dysfunction and identify innovative approaches to treat AD and other aging-related neurodegenerative disorders.

Public Health Relevance

The proposed research aims to Identify a new class of pharmacologic agents for Alzheimer's disease based on reversing newly discovered defects In the way that AD patients break down toxic proteins that accumulate in the brain. Currently, there Is no effective treatment to slow or prevent the progression of AD and our studies have the potential of Identifying such a treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG017617-14
Application #
8724304
Study Section
Special Emphasis Panel (ZAG1-ZIJ-6)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
14
Fiscal Year
2014
Total Cost
$455,889
Indirect Cost
$147,664
Name
Nathan Kline Institute for Psychiatric Research
Department
Type
DUNS #
167204762
City
Orangeburg
State
NY
Country
United States
Zip Code
10962
Alldred, Melissa J; Lee, Sang Han; Petkova, Eva et al. (2015) Expression profile analysis of vulnerable CA1 pyramidal neurons in young-Middle-Aged Ts65Dn mice. J Comp Neurol 523:61-74
Alldred, Melissa J; Lee, Sang Han; Petkova, Eva et al. (2015) Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD). Brain Struct Funct 220:2983-96
Kelley, Christy M; Powers, Brian E; Velazquez, Ramon et al. (2014) Sex differences in the cholinergic basal forebrain in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease. Brain Pathol 24:33-44
Counts, Scott E; Alldred, Melissa J; Che, Shaoli et al. (2014) Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. Neuropharmacology 79:172-9
Yan, Jian; Ginsberg, Stephen D; Powers, Brian et al. (2014) Maternal choline supplementation programs greater activity of the phosphatidylethanolamine N-methyltransferase (PEMT) pathway in adult Ts65Dn trisomic mice. FASEB J 28:4312-23
Xue, Xue; Wang, Li-Rong; Sato, Yutaka et al. (2014) Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer's disease. Nano Lett 14:5110-7
Kaur, Gurjinder; Sharma, Ajay; Xu, Wenjin et al. (2014) Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome. J Neurosci 34:5099-106
Kelley, Christy M; Powers, Brian E; Velazquez, Ramon et al. (2014) Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice. J Comp Neurol 522:1390-410
Wesson, Daniel W; Morales-Corraliza, Jose; Mazzella, Matthew J et al. (2013) Chronic anti-murine Aýý immunization preserves odor guided behaviors in an Alzheimer's ýý-amyloidosis model. Behav Brain Res 237:96-102
Nixon, Ralph A (2013) The role of autophagy in neurodegenerative disease. Nat Med 19:983-97

Showing the most recent 10 out of 105 publications